Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
9.93
Dollar change
+0.03
Percentage change
0.30
%
IndexRUT P/E- EPS (ttm)-2.16 Insider Own13.13% Shs Outstand54.99M Perf Week-8.56%
Market Cap555.19M Forward P/E- EPS next Y-2.66 Insider Trans6.71% Shs Float48.58M Perf Month-14.62%
Income-96.66M PEG- EPS next Q-0.54 Inst Own86.73% Short Float16.68% Perf Quarter-11.97%
Sales0.00M P/S- EPS this Y-10.16% Inst Trans-1.84% Short Ratio9.88 Perf Half Y-6.85%
Book/sh4.62 P/B2.15 EPS next Y-13.04% ROA-39.24% Short Interest8.10M Perf Year148.25%
Cash/sh4.68 P/C2.12 EPS next 5Y- ROE-42.82% 52W Range3.64 - 17.79 Perf YTD-29.22%
Dividend Est.- P/FCF- EPS past 5Y-105.28% ROI-37.86% 52W High-44.19% Beta2.10
Dividend TTM- Quick Ratio12.33 Sales past 5Y0.00% Gross Margin- 52W Low172.80% ATR (14)0.77
Dividend Ex-Date- Current Ratio12.33 EPS Y/Y TTM17.52% Oper. Margin0.00% RSI (14)35.37 Volatility6.35% 6.09%
Employees74 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.10 Target Price25.56
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q24.98% Payout- Rel Volume0.91 Prev Close9.90
Sales Surprise- EPS Surprise-1.98% Sales Q/Q- EarningsMar 11 AMC Avg Volume820.16K Price9.93
SMA20-9.59% SMA50-21.22% SMA200-17.91% Trades Volume744,449 Change0.30%
Date Action Analyst Rating Change Price Target Change
Apr-02-24Initiated Goldman Buy $24
Jan-30-24Initiated Citigroup Buy $20
Jul-21-23Initiated Oppenheimer Outperform $21
May-05-23Initiated CapitalOne Overweight $16
Feb-22-23Initiated Credit Suisse Outperform $12
Jul-06-22Resumed Canaccord Genuity Buy $16
Jun-09-22Upgrade H.C. Wainwright Neutral → Buy $12
Feb-28-22Initiated H.C. Wainwright Neutral
Dec-07-21Resumed Cowen Outperform
Dec-14-20Initiated JP Morgan Overweight $52
Apr-08-24 04:30PM
Apr-05-24 12:16AM
Apr-02-24 04:29PM
Mar-11-24 04:03PM
Mar-06-24 07:03AM
04:30PM Loading…
Mar-04-24 04:30PM
Feb-06-24 07:01AM
Feb-02-24 04:30PM
Jan-22-24 10:54AM
Jan-08-24 08:12AM
Jan-02-24 04:01PM
Dec-21-23 10:59AM
Dec-05-23 12:27PM
Dec-04-23 04:29PM
Dec-01-23 09:30AM
05:10PM Loading…
Nov-28-23 05:10PM
Nov-27-23 12:54PM
11:32AM
Nov-22-23 09:00AM
Nov-07-23 04:02PM
Nov-02-23 04:32PM
Nov-01-23 04:27PM
Oct-30-23 08:50AM
Oct-26-23 10:33AM
Oct-22-23 02:55AM
Oct-20-23 01:15PM
Oct-17-23 07:01AM
Oct-16-23 07:02AM
Oct-12-23 07:01AM
Oct-11-23 09:55AM
08:50AM Loading…
08:50AM
Oct-10-23 07:00AM
Oct-03-23 04:30PM
Sep-27-23 09:24PM
Sep-25-23 09:55AM
08:50AM
Sep-20-23 07:29AM
Sep-15-23 01:09PM
Sep-14-23 11:02PM
Sep-08-23 12:00PM
09:55AM
Sep-07-23 04:02PM
Sep-06-23 04:30PM
Sep-05-23 04:30PM
07:30AM
Aug-08-23 04:03PM
08:23AM
Aug-02-23 04:30PM
Aug-01-23 08:00AM
Jul-05-23 07:30AM
Jun-14-23 01:00PM
Jun-02-23 04:30PM
May-30-23 04:30PM
May-19-23 06:29AM
May-11-23 08:43AM
May-09-23 04:01PM
May-08-23 07:06AM
May-02-23 04:30PM
Apr-13-23 04:30PM
Apr-04-23 04:30PM
Mar-09-23 04:00PM
Mar-02-23 05:00PM
04:05PM
Feb-21-23 04:30PM
Feb-02-23 06:00PM
Jan-04-23 04:30PM
Jan-03-23 07:00AM
Jan-02-23 08:23AM
Dec-07-22 03:37PM
Dec-02-22 04:30PM
Nov-21-22 09:16AM
Nov-08-22 04:30PM
Nov-02-22 04:30PM
Nov-01-22 08:00AM
Oct-26-22 08:01AM
03:00AM
Oct-12-22 07:01AM
Oct-04-22 04:29PM
Sep-06-22 04:30PM
Sep-01-22 05:01PM
Aug-09-22 04:35PM
04:30PM
Aug-04-22 04:30PM
Aug-03-22 04:30PM
Jul-26-22 07:32AM
Jul-22-22 06:49AM
Jul-21-22 07:30AM
Jul-07-22 10:40AM
Jul-05-22 04:30PM
Jun-09-22 07:35AM
07:30AM
Jun-02-22 04:30PM
May-24-22 04:30PM
May-09-22 04:30PM
May-03-22 04:30PM
Apr-18-22 04:30PM
Apr-04-22 07:30AM
Mar-08-22 04:35PM
Feb-28-22 04:30PM
Feb-22-22 07:30AM
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harmon CyrusDirectorMar 28 '24Sale10.9720,000219,400826,283Mar 29 05:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERMar 18 '24Option Exercise4.8713,70066,71980,364Mar 20 05:30 PM
Harmon CyrusDirectorFeb 29 '24Sale12.4125,000310,309846,283Mar 04 05:30 PM
Harmon CyrusDirectorFeb 01 '24Sale15.565,00077,800871,283Feb 02 05:00 PM
Harmon CyrusDirectorJan 31 '24Sale12.2325,000305,750876,283Feb 02 05:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERJan 25 '24Option Exercise7.0220,000140,40066,664Jan 29 07:30 AM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Jan 12 '24Option Exercise7.0250,000351,000484,987Jan 16 07:30 AM
Harmon CyrusDirectorDec 29 '23Sale13.3825,000334,500901,283Jan 02 05:30 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Dec 12 '23Option Exercise7.0210,00070,200434,987Dec 12 05:55 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERDec 11 '23Option Exercise7.022,90020,35846,664Dec 12 05:55 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERDec 06 '23Option Exercise7.0213,10091,96243,764Dec 07 08:30 PM
Paradigm Biocapital Advisors L10% OwnerDec 06 '23Buy11.60100,0001,160,0006,590,981Dec 08 04:19 PM
Graham G. WalmsleyDirectorDec 05 '23Buy14.19131,8701,871,2801,800,000Dec 18 06:30 PM
Harmon CyrusDirectorNov 30 '23Sale12.5725,000314,250926,283Dec 01 05:15 PM
Bohen SeanPRESIDENT AND CEONov 22 '23Sale13.9027,932388,255144,925Nov 22 07:00 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Nov 22 '23Sale13.899,145127,024424,987Nov 22 07:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERNov 22 '23Sale13.897,09598,55030,664Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 22 '23Sale13.896,65392,410574,099Nov 22 07:00 PM
Harmon CyrusDirectorNov 22 '23Sale13.903,98955,447951,283Nov 22 07:00 PM
Bohen SeanPRESIDENT AND CEONov 21 '23Sale14.8829,293435,879172,857Nov 22 07:00 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Nov 21 '23Sale14.869,597142,632434,132Nov 22 07:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERNov 21 '23Sale14.847,461110,74737,759Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 21 '23Sale14.886,976103,823580,752Nov 22 07:00 PM
Harmon CyrusDirectorNov 21 '23Sale14.864,19262,293955,272Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 08 '23Sale17.612003,522561,270Nov 13 05:30 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 03 '23Sale17.515419,473561,470Nov 03 09:39 PM
Harmon CyrusDirectorNov 02 '23Sale15.645,00078,200943,714Nov 02 08:50 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 02 '23Sale15.363,33251,180562,011Nov 03 09:39 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 01 '23Sale15.026,668100,153565,343Nov 03 09:39 PM
Harmon CyrusDirectorOct 31 '23Sale12.0525,000301,250948,714Nov 02 08:50 PM
Harmon CyrusDirectorSep 29 '23Sale12.4125,000310,250973,714Oct 03 05:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSep 19 '23Sale12.6720,000253,400572,011Sep 21 05:00 PM
BVF PARTNERS L P/ILDirectorSep 12 '23Buy9.841,505,93214,818,3714,688,954Sep 14 04:25 PM
Graham G. WalmsleyDirectorSep 12 '23Buy9.84508,1304,999,9991,668,130Dec 18 06:30 PM
Harmon CyrusDirectorSep 05 '23Sale11.6210,000116,200998,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 31 '23Sale9.3615,000140,4001,008,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 16 '23Sale10.1415,000152,1001,023,714Aug 17 05:00 PM
Harmon CyrusDirectorJun 08 '23Sale6.3010,00063,0001,038,714Jun 09 05:30 PM
Harmon CyrusDirectorJun 06 '23Sale6.295,00031,4751,048,714Jun 07 09:30 PM
Harmon CyrusDirectorJun 05 '23Sale6.045,00030,2251,053,714Jun 07 09:30 PM